These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21877924)

  • 1. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.
    Mori Y; Taniguchi Y; Sezaki K; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2011 Nov; 13(11):1139-44. PubMed ID: 21877924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
    Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.
    Inoue K; Maeda N; Kashine S; Fujishima Y; Kozawa J; Hiuge-Shimizu A; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2011 Dec; 10():109. PubMed ID: 22132774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    He YL; Foteinos G; Neelakantham S; Mattapalli D; Kulmatycki K; Forst T; Taylor A
    Diabetes Obes Metab; 2013 Dec; 15(12):1111-9. PubMed ID: 23782529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Nauck M; Frid A; Hermansen K; Shah NS; Tankova T; Mitha IH; Zdravkovic M; Düring M; Matthews DR;
    Diabetes Care; 2009 Jan; 32(1):84-90. PubMed ID: 18931095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR
    Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Li LQ; Yao MY; Ma JX; Xue P; Li YK
    Endocr J; 2019 Oct; 66(10):871-880. PubMed ID: 31243192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
    Horie I; Haraguchi A; Sako A; Akeshima J; Niri T; Shigeno R; Ito A; Nozaki A; Natsuda S; Akazawa S; Mori Y; Ando T; Kawakami A; Abiru N
    Diabetes Res Clin Pract; 2018 Oct; 144():161-170. PubMed ID: 30194951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
    Garber A; Henry R; Ratner R; Garcia-Hernandez PA; Rodriguez-Pattzi H; Olvera-Alvarez I; Hale PM; Zdravkovic M; Bode B;
    Lancet; 2009 Feb; 373(9662):473-81. PubMed ID: 18819705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.
    Sullivan SD; Alfonso-Cristancho R; Conner C; Hammer M; Blonde L
    Pharmacotherapy; 2009 Nov; 29(11):1280-8. PubMed ID: 19873688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
    Chiefari E; Capula C; Vero A; Oliverio R; Puccio L; Liguori R; Pullano V; Greco M; Foti D; Tirinato D; Vero R; Brunetti A
    Diabetes Technol Ther; 2015 Jul; 17(7):468-74. PubMed ID: 25844858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
    Nagakura J; Yamakawa T; Taguri M; Tsuchiya H; Shigematsu E; Suzuki J; Morita S; Kadonosono K; Terauchi Y
    Endocr J; 2016; 63(3):239-47. PubMed ID: 26743240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.
    Irace C; Fiorentino R; Carallo C; Scavelli F; Gnasso A
    Diabetes Technol Ther; 2011 Dec; 13(12):1261-3. PubMed ID: 21751893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
    Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
    Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
    Mateos JL; Wajchenberg BL
    Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Nishida T; Kaku K
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.